Fluorine cardiovascular magnetic resonance angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agents.

While the current gold standard for coronary imaging is X-ray angiography, evidence is accumulating that it may not be the most sensitive technique for detecting unstable plaque. Other imaging modalities, such as cardiovascular magnetic resonance (CMR), can be used for plaque characterization, but suffer from long scan and reconstruction times for determining regions of stenosis. We have developed an intravascular fluorinated contrast agent that can be used for angiography with cardiovascular magnetic resosnace at clinical field strengths (1.5 T). This liquid perfluorocarbon nanoparticle contains a high concentration of fluorine atoms that can be used to generate contrast on 19F MR images without any competing background signal from surrounding tissues. By using a perfluorocarbon with 20 equivalent fluorine molecules, custom-built RF coils, a modified clinical scanner, and an efficient steady-state free procession sequence, we demonstrate the use of this agent for angiography of small vessels in vitro, ex vivo, and in vivo. The surprisingly high signal generated with very short scan times and low doses of perfluorocarbon indicates that this technique may be useful in clinical settings when coupled with advanced imaging strategies.

[1]  Samuel A Wickline,et al.  Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. , 2004, Magnetic resonance in medicine.

[2]  P. Joseph,et al.  In Vivo 19F NMR Imaging of the Cardiovascular System , 1985, Journal of computer assisted tomography.

[3]  Z. Fayad,et al.  Imaging of atherosclerosis. Coronary wall imaging with MRI. , 2002, Journal of cardiovascular risk.

[4]  S A Wickline,et al.  Novel MRI Contrast Agent for Molecular Imaging of Fibrin: Implications for Detecting Vulnerable Plaques , 2001, Circulation.

[5]  Eric T Ahrens,et al.  In vivo imaging platform for tracking immunotherapeutic cells , 2005, Nature Biotechnology.

[6]  S. Flaim Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.

[7]  Z. Fayad,et al.  Coronary Wall Imaging with MRI , 2002 .

[8]  Patrick J. Gaffney,et al.  Quantitative “magnetic resonance immunohistochemistry” with ligand‐targeted 19F nanoparticles , 2004 .

[9]  P. Antich,et al.  Regional myocardial oxygen tension: 19F MRI of sequestered perfluorocarbon , 1996, Magnetic resonance in medicine.

[10]  P. Antich,et al.  Regional tumor oxygen dynamics: 19F PBSR EPI of hexafluorobenzene. , 1997, Magnetic resonance imaging.

[11]  W. Santamore,et al.  Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? , 1988, Circulation.

[12]  Donald S. Williams,et al.  MRI of lungs using partial liquid ventilation with water‐in‐perfluorocarbon emulsions , 2002, Magnetic resonance in medicine.

[13]  H. Kauczor,et al.  19F‐MRI of perflubron for measurement of oxygen partial pressure in porcine lungs during partial liquid ventilation , 2002, Magnetic resonance in medicine.

[14]  C. Zarins,et al.  Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.

[15]  L. J. Busse,et al.  Deconvolution techniques for removing the effects of chemical shift in 19F nuclear magnetic resonance imaging of perfluorocarbon compounds. , 1986, Medical physics.

[16]  E. Topol,et al.  Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. , 1995, Circulation.

[17]  Sheng-Kwei Song,et al.  Improved molecular imaging contrast agent for detection of human thrombus , 2003, Magnetic resonance in medicine.

[18]  K. Scheffler,et al.  Principles and applications of balanced SSFP techniques , 2003, European Radiology.

[19]  D Li,et al.  Magnetic resonance imaging of coronary arteries. , 2001, Topics in magnetic resonance imaging : TMRI.

[20]  P. Antich,et al.  Tumor oximetry: demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging in the Dunning prostate R3327-AT1 rat tumor. , 2001, International journal of radiation oncology, biology, physics.

[21]  Richard D. White,et al.  Coronary imaging: angiography shows the stenosis, but IVUS, CT, and MRI show the plaque. , 2003, Cleveland Clinic journal of medicine.

[22]  Shelton D Caruthers,et al.  In Vitro Demonstration Using 19F Magnetic Resonance to Augment Molecular Imaging With Paramagnetic Perfluorocarbon Nanoparticles at 1.5 Tesla , 2006, Investigative radiology.

[23]  Kerry K. Karukstis,et al.  Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis , 2002, Circulation.

[24]  P. Antich,et al.  Tumor oxygen tension: measurement using Oxygent as a 19F NMR probe at 4.7 T. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.

[25]  M. Davies,et al.  Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries. , 1996, Circulation.

[26]  M. Graves,et al.  Magnetic resonance angiography. , 1997, The British journal of radiology.

[27]  B R Rosen,et al.  In Vivo 19F NMR Imaging , 1985, Journal of computer assisted tomography.

[28]  J. Ackerman,et al.  Perfluorinated organic liquids and emulsions as biocompatible NMR imaging agents for 19F and dissolved oxygen. , 1984, Advances in experimental medicine and biology.

[29]  René M. Botnar,et al.  Coronary magnetic resonance angiography for the detection of coronary stenoses. , 2001, The New England journal of medicine.

[30]  Valentin Fuster,et al.  Intravascular Modalities for Detection of Vulnerable Plaque: Current Status , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[31]  Xiaobing Fan,et al.  Effect of carbogen on tumor oxygenation: combined fluorine-19 and proton MRI measurements. , 2002, International journal of radiation oncology, biology, physics.

[32]  A Haase,et al.  19F‐MRI in vivo determination of the partial oxygen pressure in perfluorocarbon‐loaded alginate capsules implanted into the peritoneal cavity and different tissues , 1999, Magnetic resonance in medicine.

[33]  L. Hedlund,et al.  Magnetic resonance angiography with hyperpolarized 129Xe dissolved in a lipid emulsion , 1999, Magnetic resonance in medicine.

[34]  L. J. Busse,et al.  Deconvolution of chemical shift spectra in two- or three-dimensional [19F] MR imaging. , 1988, Journal of computer assisted tomography.